Literature DB >> 6300367

Kinetic study of smoking marijuana.

G Barnett, C W Chiang, M Perez-Reyes, S M Owens.   

Abstract

Six subjects each smoked a 1% marijuana cigarette and 2 hr later smoked a second one. Plasma levels of delta-9-tetrahydrocannabinol were measured for 9 hr with a radioimmunoassay. Heart rate and self-reported "high" were measured for 2 hr after each cigarette. All three measures showed a rapid increase after the start of smoking with Cmax occurring before the end of smoking. There was a strong correlation between decrease in heart rate and plasma levels from 10 min after smoking until 120 min. All pharmacodynamic response measures returned to baseline values within approximately 2 hr.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6300367     DOI: 10.1007/bf01059033

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

1.  Constituents of Cannabis sativa L. XI: Cannabidiol and cannabichromene in samples of known geographical origin.

Authors:  J H Holley; K W Hadley; C E Turner
Journal:  J Pharm Sci       Date:  1975-05       Impact factor: 3.534

2.  The clinical pharmacology and dynamics of marihuana cigarette smoking.

Authors:  M Perez-Reyes; S M Owens; S Di Guiseppi
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

3.  Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.

Authors:  S Agurell; S Carlsson; J E Lindgren; A Ohlsson; H Gillespie; L Hollister
Journal:  Experientia       Date:  1981-10-15

Review 4.  Constituents of Cannabis sativa L. XVII. A review of the natural constituents.

Authors:  C E Turner; M A Elsohly; E G Boeren
Journal:  J Nat Prod       Date:  1980 Mar-Apr       Impact factor: 4.050

5.  Further urinary metabolites of delta 1-tetrahydrocannabinol in man.

Authors:  M M Halldin; L K Andersson; M Widman; L E Hollister
Journal:  Arzneimittelforschung       Date:  1982

6.  Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.

Authors:  A Ohlsson; J E Lindgren; A Wahlen; S Agurell; L E Hollister; H K Gillespie
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

7.  125I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method.

Authors:  S M Owens; A J McBay; H M Reisner; M Perez-Reyes
Journal:  Clin Chem       Date:  1981-04       Impact factor: 8.327

8.  Urinary metabolites of delta 1-tetrahydrocannabinol in man.

Authors:  M M Halldin; S Carlsson; S L Kanter; M Widman; S Agurell
Journal:  Arzneimittelforschung       Date:  1982

9.  Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.

Authors:  C A Hunt; R T Jones; R I Herning; J Bachman
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

10.  Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.

Authors:  J E Lindgren; A Ohlsson; S Agurell; L Hollister; H Gillespie
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more
  10 in total

1.  Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Authors:  Jules A A C Heuberger; Zheng Guan; Olubukayo-Opeyemi Oyetayo; Linda Klumpers; Paul D Morrison; Tim L Beumer; Joop M A van Gerven; Adam F Cohen; Jan Freijer
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

2.  Ethnopharmacological table on some reputedly psychoactive fumigatories among Middle and South American natives.

Authors:  P A De Smet
Journal:  Pharm Weekbl Sci       Date:  1985-10-25

3.  Behavioral pharmacokinetics of marijuana.

Authors:  G Barnett; V Licko; T Thompson
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana.

Authors:  E Johansson; M M Halldin; S Agurell; L E Hollister; H K Gillespie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.

Authors:  Claudine C Hunault; Tjeert T Mensinga; Irma de Vries; Hermien H Kelholt-Dijkman; Jani Hoek; Maaike Kruidenier; Marianne E C Leenders; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2008-08-10       Impact factor: 4.530

7.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

8.  Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.

Authors:  David M Schwope; Wendy M Bosker; Johannes G Ramaekers; David A Gorelick; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2012-05-15       Impact factor: 3.367

9.  Development and Verification of a Linked Δ 9-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women.

Authors:  Gabriela I Patilea-Vrana; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2021-05-05       Impact factor: 3.579

10.  Prenatal Exposure to Delta-9-tetrahydrocannabinol (THC) Alters the Expression of miR-122-5p and Its Target Igf1r in the Adult Rat Ovary.

Authors:  Annia A Martínez-Peña; Kendrick Lee; Madison Pereira; Ahmed Ayyash; James J Petrik; Daniel B Hardy; Alison C Holloway
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.